Darwin Global Management, Ltd. Argenx Se Transaction History

Darwin Global Management, Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $84.1 Million - $125 Million	-227,728 Reduced 83.31%	45,615 $22.4 Million
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $4.27 Million - $5.01 Million	-11,855 Reduced 4.16%	273,343 $107 Million
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $4.18 Million - $5.05 Million	-12,503 Reduced 4.2%	285,198 $106 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $102 Million - $120 Million	297,701 New	297,701 $113 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

Stay updated on Darwin Global Management, Ltd. with notifications on news.